IDT Biologika is an innovative privately-held company with more than 90 years of experience in research, development, manufacture and distribution of biologics for the global protection of human and animal health. With the expertise and capacity to handle large-scale campaign production of human vaccines and biopharmaceuticals, IDT Biologika brings development, testing and regulatory excellence along with state-of-the-art manufacturing lines required to advance projects with the highest level of quality, efficiency and consistency of supply.
Recognized for its technically sophisticated development, manufacture and handling of biopharmaceuticals and lyophilized compounds in EMA- and FDA-inspected facilities, IDT Biologika has developed into one of the world's leading pharmaceutical and biotechnological companies with a focus on three core areas: animal health, vaccines and pharmaceuticals. In 2015, IDT Biologika achieved sales of approximately €172 million, employing 1,250 employees.
Operationally, in Denmark, the Netherlands, Belgium, France and Spain, IDT runs distribution branches whose activities are focused primarily on the animal health business segment. Contract manufacturing services for human pharmaceuticals and vaccines are provided worldwide. In the United States, IDT Biologika Corp. is responsible for sales activities throughout North America. The company's production facilities are located in the BioPharmaPark of Dessau-Rosslau and the Riems district of Greifswald, Germany. IDT Biologika is a member of the Klocke Holding Group.